MarketPulse

DCCR drug

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Soleno Therapeutics Hit with Class Action Over Undisclosed Safety Data on DCCR Candidate

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Soleno Therapeutics Faces Class Action Over Undisclosed Drug Safety Issues

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Soleno Therapeutics Faces Securities Fraud Lawsuit Over DCCR Safety Disclosures

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR safety concerns, patient death, and disappointing Q3 results that triggered sharp stock declines.
SLNOsecurities fraudclass action lawsuit
BenzingaBenzinga··Glancy Prongay Wolke & Rotter Llp

Soleno Therapeutics Faces Securities Fraud Lawsuit Over DCCR Safety Claims

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR drug safety concerns, patient death, and disappointing Q3 results.
SLNOsecurities fraudclass action lawsuit
BenzingaBenzinga··Law Offices Of Howard G. Smith

Soleno Therapeutics Faces Securities Fraud Suit Over DCCR Drug; Deadline Looms

Soleno Therapeutics ($SLNO) faces securities fraud lawsuit over DCCR drug for Prader-Willi syndrome. Stock plunged following safety concerns, patient death, and weak Q3 results.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Soleno Therapeutics Faces Class Action Over Undisclosed DCCR Safety Concerns

Soleno Therapeutics faces class action lawsuit alleging failure to disclose safety concerns about DCCR drug candidate from clinical trials.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Drug

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Soleno Therapeutics Faces Class Action Over Alleged PWS Drug Safety Misstatements

Class action lawsuit filed against $SLNO alleging false statements about DCCR safety concerns and commercial viability for Prader-Willi syndrome treatment.
SLNOsecurities fraudclass action lawsuit